secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001193125-23-292121
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports 100% of evaluable patients in Phase 1 INB-100 trial remain in complete remission
--------------------------------------------------------------------------------

- All 10 evaluable patients alive, progression-free, and in durable CR as of Nov 3, 2023; 6 relapse-free for over 1 year.
- No dose-limiting toxicities observed; low-grade acute GVHD in 60% of patients.
- Gamma-delta T cells expanded and persisted >365 days post single dose; dose response shows 48.9x greater at day 60 for DL 2 vs HSCT alone.
- Two patients progression-free for over 3 years; individual follow-up ranges 4.9 to 42.7 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523292121/0001193125-23-292121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523292121/d747940d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-292121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer